New York, June 1, 2026, 05:01 (EDT)
- Aveanna finished Friday at $7.17, off 2.18%. Volume was 1.7 million shares.
- Routine shareholder approvals came out of the company’s May 29 annual meeting, according to its latest filing.
- Management is set to appear next for investors at William Blair’s growth conference on June 2.
Aveanna Healthcare Holdings Inc. shares are back in focus as premarket action opens Monday, following a down day Friday. Investors are watching a standard shareholder vote, recent debt repricing, and an investor presentation set for Tuesday. Aveanna finished at $7.17 on May 29, a drop of 2.18%, based on its historical pricing chart.
Timing is key here. Nasdaq’s premarket was active at the dateline, but normal hours are 9:30 a.m. to 4:00 p.m. Eastern. June 1 isn’t marked on Nasdaq’s 2026 U.S. holiday list.
Aveanna said in a new 8-K after Friday’s annual meeting that shareholders voted in Rodney D. Windley, Sam Weil and Steven E. Rodgers as Class II directors, signed off on Ernst & Young as auditor for the year ending Jan. 2, 2027, and approved executive pay in a non-binding say-on-pay vote. The filing also said no other items came up.
Aveanna’s main concern right now is the cost on its balance sheet. Last week, the company said it reworked rates on its first-lien credit facility and revolving credit facility. Margins came down by 50 basis points, or half a percent. A basis point is one-hundredth of a percentage point.
Chief Financial Officer Matt Buckhalter said the deal is aimed at “strengthen[ing] the balance sheet” and allows the company more room for growth plans. The new facilities are made up of $1.318 billion in senior secured term loans and a $250 million revolving credit line, the company said. SEC
Aveanna’s debt stood at $1.48 billion on April 4, and borrowing costs keep mattering for the stock. The company listed $189.3 million in cash and a revolver it hasn’t touched, with $225.5 million available.
Aveanna delivered better results this quarter. First-quarter revenue came in at $647.9 million, up 15.9% on the year. Net income climbed to $41.7 million versus $5.2 million a year earlier. Adjusted EBITDA rose 25.2% to $84.4 million. CEO Jeff Shaner pointed to “strength and resiliency” in the business. The company also raised its 2026 revenue outlook to $2.56 billion-$2.58 billion and sees adjusted EBITDA at $328 million-$332 million. SEC
The stock trailed the main indexes Friday. The Nasdaq Composite added 0.20% to 26,972.62, and the S&P 500 was up 0.22% at 7,580.06.
Peer reaction is uneven. Shares of Addus HomeCare, Pennant Group and Chemed—considered comps for home care and hospice services—also finished lower Friday. Addus dropped 1.9%, Pennant eased 0.4% and Chemed fell 3.1%, market data showed.
Sector appetite is still around. In a Reuters story about Enhabit’s go-private transaction this year, Oppenheimer analyst Michael Wiederhorn said investors might be leaving “an attractive long-term opportunity from home health” on the table. He cited better reimbursement and organic growth. Reuters
Aveanna management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2 at 2:40 p.m. CST and hold one-on-ones with investors that day. Investors get a chance to press on leverage, payer rates and whether the new guidance could go higher.
Aveanna’s outlook is still murky. The company has flagged risks from Medicare and Medicaid changes, managed-care reimbursement, higher wages, staffing gaps, acquisition exposure and big debt. Narrower interest margins are a positive, but risks stick around.
For Monday, the main issue is if investors see the repricing as enough after Friday’s drop. The first sign likely shows up when regular trading starts, but the clearer signal comes Tuesday as management steps in front of the conference crowd.
